AB-1001 Gene Therapy ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 1 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05541627 (ClinicalTrials.gov) | October 12, 2022 | 13/9/2022 | A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | An Open-Label Phase I/II Dose Finding Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of AB-1001 in Adult Subjects With Early Manifest Huntington's Disease (HD) | Huntington Disease | Genetic: AB-1001 Gene Therapy | Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | NULL | Recruiting | 18 Years | 65 Years | All | 18 | Phase 1/Phase 2 | France |